Top5 salary levels for popular jobs in the healthcare sector are announced.

Recently, the country's largest compensation database platform pay intelligence released the first half of 2020 market pay white paper.
The white paper covers eight sectors, including the Internet, finance, real estate, medicine, consumer goods, education, manufacturing and media, and includes a full sample of pay increases in all eight sectors, up from 8.1% in the fourth quarter of 2019 due to the impact of the outbreak. 29% fell sharply to 1.47% in the first quarter of 2020, and it was not until the second quarter of 2020 that there was a certain rebound, rising to 2.23%, but still a significant gap from 8.47% in the same period last year.
Among the eight major industries, the pharmaceutical industry's pay adjustment bucked the trend, with pay increases of 15.19% and 16.89 percent in the first and second quarters of this year, respectively, up from 13.07 percent and 15.84 percent in the same period last year.
overall pay rise in the first half of 2020, while falling to 8.63 per cent in the first quarter, was much higher than in other sectors and quickly rose to 13.26 per cent in the second quarter.
specific to the medical sub-sectors, different sub-sectors, pay increases vary.
data show that the biopharmaceutical industry had the highest pay increase, at 14.85 per cent, followed by medical consulting at 11.63 per cent and medical beauty at 1.96 per cent. The impact is huge, according to the latest Chinese medical services market data released by Frost Sullivan, the impact of the outbreak, the medical and U.S. industry growth is expected to be only 5.7% in 2020, far lower than the 18% growth rate in 2019.
"This cliff-edge decline is at least the slowest pace in at least the last 10 years," Venus, CEO of China Medical America's first new oxygen technology unit, said in an interview with Megyn Valley at the Mayworth Forum last month.
"also notable, the white paper also released medical devices, pharmaceutical chain hot jobs TOP5 pay data.
the annual fixed salary and total annual cash income of these popular positions are measured as points, which mainly reflect the state of the market's compensation level.
10 indicates that 10% of the data is less than this value, reflecting the low end of the market, the 50th bit indicates that 50% of the data is less than this value, reflecting the median level of the market, and the 90th minute indicates that 90% of the data is less than this value, reflecting the high end of the market.
sales positions in the medical consulting, medical devices, medical chain income is relatively high, to medical consulting sales representative position, for example, its annual fixed salary average of 83.671 million yuan, the average annual total cash income of 124.133 million yuan, the mid-level value of 76.154 million yuan and 114.281 million yuan, respectively.
Compared with medical consulting, the sales representative income of medical devices is slightly lower, with an average annual fixed salary of $745.61 million, an average annual cash income of $110.619 million, and a mid-range level of $678.63 million and $101.839 million, respectively.
average annual fixed salary of sales representatives of the pharmaceutical chain was RMB832.32 million, the average annual total cash income was RMB123.483 million, and the mid-range level value was RMB757.55 million and RMB113.682 million, respectively.
is also worth mentioning that the base salary and income of regional directors, sales managers, and investment managers are much higher than those of sales representatives.
On average, the regional director's fixed annual salary is 198248, the annual total income is 253919, the sales manager's fixed annual salary is 166522, the annual total income is 287053, the investment manager's fixed annual salary is 182024., the annual total income is 227742.
This also means that the gradual implementation of national collection and tend to normalize, and related functional departments to vigorously combat the "gold sales" policy under high pressure, such as September 16, the State Health Insurance Administration issued "on the establishment of pharmaceutical prices and credit evaluation system guidance", the industry commonly known as the "industry blacklist system" officially launched.
"evaluation system" is to rate pharmaceutical enterprises, once because of commercial bribery and other illegal acts are investigated, it becomes a deduction.
the blacklisting of pharmaceutical companies will seriously affect drug sales.
provinces have made it clear that companies that are tainted by bribery will be kicked off the procurement list.
in an increasingly tough environment, pharmaceutical representatives want to continue in the field, but also to pursue higher pay, only promotion will have the possibility of a pay rise.
.